scholarly journals CAN THE PRESENCE OF ATRIAL FIBRILLATION INFLUENCE THE LEVELS OF HEART FAILURE - SPECIFIC BIOMARKERS IN OVERWEIGHT AND OBESE PATIENTS WITH HEART FAILURE?

2019 ◽  
Vol 70 (6) ◽  
pp. 2294-2300
Author(s):  
Alexandra Dadarlat ◽  
Dana Pop ◽  
Anca Daniela Farcas ◽  
Dumitru Zdrenghea ◽  
Gyorgy Bodizs ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
High Morbidity ◽  
Obese Patients ◽  
Chemiluminescence Method ◽  
Diagnosis And Prognosis ◽  
A Value ◽  
Patients With Heart Failure ◽  
Galectin 3

Heart failure continues to be a major worldwide medical issue, associated with high morbidity and mortality. The need for ideal biomarkers to aid the diagnosis and prognosis in certain situations, such as obesity or atrial fibrillation is still ongoing. Obese patients are commonly hyperleptinemic. The aim of the study is to assess the role of several biomarkers in overweight and obese patients diagnosed with heart failure, depending on the presence or absence of atrial fibrillation and also their relationship with leptin. The study included 88 overweight and obese patients, with a body mass index (BMI) ≥25 kg/m2, admitted for worsening heart failure. Of these, 52.2% had atrial fibrillation. Dosage of NT-proBNP was performed using the chemiluminescence method. MR-proANP, galectin-3 and leptin were dosed using the ELISA method. A value of P [0.05 was defined as statistically significant. The values of natriuretic peptides NT-proBNP and MR-proANP were significantly increased. Only NT-proBNP was significantly influenced by renal function. No statistically significant correlation was found between heart failure-specific biomarkers and leptin secretion. There were no significant differences in the biomarkers levels between the 2 groups of patients. No statistically significant correlation was found between heart failure-specific biomarkers and leptin secretion. Obese patients with heart failure had significantly increased values of all the studied parameters, but the presence of atrial fibrillation did not influence their levels. High leptin levels were not directly correlated with the levels of heart failure-specific biomarkers.

scholarly journals Interleukin-6 Could Be a Potential Prognostic Factor in Ambulatory Elderly Patients with Stable Heart Failure: Results from a Pilot Study

2021 ◽  
Vol 10 (3) ◽  
pp. 504
Author(s):  
Marina Povar-Echeverría ◽  
Pablo Esteban Auquilla-Clavijo ◽  
Emmanuel Andrès ◽  
Francisco Javier Martin-Sánchez ◽  
María Victoria Laguna-Calle ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Renal Failure ◽  
Interleukin 6 ◽  
Kaplan Meier ◽  
Patients With Heart Failure ◽  
Potential Prognostic Factor ◽  
Fundamental Phenomenon ◽  
Group 2

Introduction: Inflammation is a fundamental phenomenon in heart failure, but the prognostic or therapeutic role of markers such as interleukin-6 (IL-6) has not yet been clarified. The objective of this study is to describe the clinical profile of patients with elevated IL-6 and determine if they have worse clinical outcomes. Methods: A retrospective c.ohort observational study including 78 patients with heart failure followed up at the Heart Failure Outpatient Clinic of the Internal Medicine Department. IL-6 was determined in all patients, who were then assigned into two groups according to IL-6 level (normal or high). Clinical and prognostic data were collected to determine the differences in both groups. Results: The average age was 79 years, 60% female. A total of 53.8% of the patients had elevated IL-6 (group 2). Patients with elevated IL-6 presented more frequently with anemia mellitus (64.3% vs. 41.7%; p = 0.046), atrial fibrillation (83.3% vs. 61.9% p = 0.036), dyslipidemia (76.2% vs. 58.2%; p = 0.03), higher creatinine levels (1.35 mg/dL vs. 1.08 mg/dL; p = 0.024), lower glomerular filtration rate (43.6 mL/min/m2 vs. 59.9 mL/min/m2; p = 0.007), and anemia 25% vs. 52.4% p = 0.014. The factors independently associated with the increase in IL-6 were anemia 3.513 (1.163–10.607) and renal failure 0.963 (0.936–0.991), p < 0.05. Mortality was higher in the group with elevated IL-6 levels (16% vs. 2%; p = 0.044) with a log-rank p = 0.027 in the Kaplan–Meier curve. Conclusion: Patients with heart failure and elevated IL-6 most often have atrial fibrillation, diabetes mellitus, dyslipidemia, anemia, and renal failure. In addition, mortality was higher and a tendency of higher hospital admission was observed in stable HF patients with elevated IL-6.

The role of atrial fibrillation catheter ablation in patients with heart failure

2021 ◽  
Vol 66 ◽  
pp. 80-85
Author(s):  
Michael L. Bernard ◽  
Francis Benn ◽  
Cody M. Williams ◽  
A. Elise Hiltbold ◽  
Paul A. Rogers ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Catheter Ablation ◽  
Patients With Heart Failure

scholarly journals The Novel Perspectives Opened by ST2 in the Pandemic: A Review of Its Role in the Diagnosis and Prognosis of Patients with Heart Failure and COVID-19

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 175
Author(s):  
Radu-Stefan Miftode ◽  
Antoniu Octavian Petriș ◽  
Viviana Onofrei Aursulesei ◽  
Corina Cianga ◽  
Irina-Iuliana Costache ◽  
...  
Keyword(s):  
Heart Failure ◽  
Myocardial Injury ◽  
Clinical Manifestations ◽  
The Novel ◽  
Inflammatory Biomarker ◽  
Diagnosis And Prognosis ◽  
Cardiovascular Comorbidities ◽  
Patients With Heart Failure ◽  
Cardioprotective Effects

The increasing incidence of coronavirus disease 19 (COVID-19) and its polymorphic clinical manifestations due to local and systemic inflammation represent a high burden for many public health systems. Multiple evidence revealed the interdependence between the presence of cardiovascular comorbidities and a severe course of COVID-19, with heart failure (HF) being incriminated as an independent predictor of mortality. Suppression of tumorigenicity-2 ST2 has emerged as one of the most promising biomarkers in assessing the evolution and prognosis of patients with HF. The uniqueness of ST2 is determined by its structural particularities. Its transmembrane isoform exerts cardioprotective effects, while the soluble isoform (sST2), which is detectable in serum, is associated with myocardial fibrosis and poor outcome in patients with HF. Some recent data also suggested the potential role of sST2 as a marker of inflammation, while other studies highlighted it as a valuable prognostic factor in patients with COVID-19. In this review, we summarized the pathways by which sST2 is related to myocardial injury and its connection to the severity of inflammation in patients with COVID-19. Also, we reviewed possible perspectives of using it as a dual cardio-inflammatory biomarker, for both early diagnosis, risk stratification and prognosis assessment of patients with concomitant HF and COVID-19.

scholarly journals The Role of Galectin-3 and ST2 in Cardiology: A Short Review

Biomolecules ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1167
Author(s):  
Ana Merino-Merino ◽  
Jeronimo Gonzalez-Bernal ◽  
Dario Fernandez-Zoppino ◽  
Ruth Saez-Maleta ◽  
Jose-Angel Perez-Rivera
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Coronary Heart Disease ◽  
Cardiac Remodeling ◽  
Short Review ◽  
Cardiac Diseases ◽  
Myocardial Cells ◽  
Prognostic Role ◽  
Galectin 3

Galectin-3 is a lectin that binds beta-galactosides. It is involved in cardiac remodeling and fibrosis through the activation of macrophages and fibroblasts. ST2 is secreted by myocardial cells due to cardiac overload. These two biomarkers have been traditionally studied in the field of heart failure to guide medical therapy and detect the progression of the disease. Nevertheless, there are novel evidences that connect galectin-3 and ST2 with coronary heart disease and, specifically, with atrial fibrillation. The aim of this article is to concisely review the diagnostic and prognostic role of galectin-3 and ST2 in different cardiac diseases.

scholarly journals Prognostic Value of Galectin-3 in Patients with Heart Failure

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Ivica Bošnjak ◽  
Kristina Selthofer-Relatić ◽  
Aleksandar Včev
Keyword(s):  
Heart Failure ◽  
Prognostic Value ◽  
Disease Modifying Drugs ◽  
Reduced Ejection Fraction ◽  
Patients With Heart Failure ◽  
Galectin 3 ◽  
Myocardial Remodelling ◽  
Lectin Family ◽  
Disease Modifying

Galectins are a family of solubleβ-galactoside-binding lectins that have important role in inflammation, immunity, and cancer. Galectin-3 as a part of this lectin family plays a very important role in development of heart failure. According to recent papers, galectin-3 plasma level correlates with heart failure outcome, primarily with rehospitalisation and death from heart failure. This paper summarizes the most recent advances in galectin-3 research, with the accent on the role of galectin-3 in pathophysiology of myocardial remodelling and heart failure development—with preserved and reduced ejection fraction, and some implication on development of new disease modifying drugs.

scholarly journals Role of galectin -3 in diagnostics and treatment control in patients with heart failure

2018 ◽  
Vol 13 (4) ◽  
Author(s):  
Vladimir Kukes ◽  
Karine Gyamdzhyan ◽  
Anna Zhestovskaia ◽  
Yury Olefir ◽  
Valeriy Marinin ◽  
...  
Keyword(s):  
Heart Failure ◽  
Treatment Control ◽  
Patients With Heart Failure ◽  
Galectin 3

The Role of Antithrombotic Therapy in Heart Failure

2020 ◽  
Vol 26 (23) ◽  
pp. 2735-2761
Author(s):  
Christina Chrysohoou ◽  
Nikolaos Magkas ◽  
Christos-Konstantinos Antoniou ◽  
Panagiota Manolakou ◽  
Aggeliki Laina ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Antithrombotic Therapy ◽  
Left Ventricular Ejection ◽  
Heart Failure Patients ◽  
Patients With Heart Failure ◽  
Artery Disease

: Heart failure is a major contributor to global morbidity and mortality burden affecting approximately 1-2% of adults in developed countries, mounting to over 10% in individuals aged >70 years old. Heart failure is characterized by a prothrombotic state and increased rates of stroke and thromboembolism have been reported in heart failure patients compared with the general population. However, the impact of antithrombotic therapy on heart failure remains controversial. Administration of antiplatelet or anticoagulant therapy is the obvious (and well-established) choice in heart failure patients with cardiovascular comorbidity that necessitates their use, such as coronary artery disease or atrial fibrillation. In contrast, antithrombotic therapy has not demonstrated any clear benefit when administered for heart failure per se, i.e. with heart failure being the sole indication. Randomized studies have reported decreased stroke rates with warfarin use in patients with heart failure with reduced left ventricular ejection fraction, but at the expense of excessive bleeding. Non-vitamin K oral anticoagulants have shown a better safety profile in heart failure patients with atrial fibrillation compared with warfarin, however, current evidence about their role in heart failure with sinus rhythm is inconclusive and further research is needed. In the present review, we discuss the role of antithrombotic therapy in heart failure (beyond coronary artery disease), aiming to summarize evidence regarding the thrombotic risk and the role of antiplatelet and anticoagulant agents in patients with heart failure.

Sign in / Sign up

Export Citation Format

Share Document